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Background: Hypertension is a global health problem. Multiple classes of drugs including
angiotensin receptor blockers (ARBs) are available for the treatment of hypertension.
Olmesartan is a relatively newer ARB used in hypertension management.
Objective: To assess the efficacy and safety of WIN-BP (Olmesartan 20 mg/40 mg) tablet in
Indian patients with hypertension.
Material and methods: An open label, non-comparative, multi-centric, real world post mar-
keting observational study included Indian adult hypertensive patients who were treated
with olmesartan 20 mg/40 mg tablet once daily for six months. The primary outcome was
reduction of systolic blood pressure (SBP) to <140 mmHg and diastolic BP (DBP) to
<90 mmHg at 3 and 6 months after initiation of treatment with olmesartan. All reported
adverse events were recorded.
Results: A total of 8940 patients were enrolled in this study. Baseline SBP of 164 mmHg was
reduced to 153, 145, 134 and 130 mmHg at the end of 15 days, 1, 3 and 6 months respec-
tively. Similarly, baseline DBP of 100 mmHg was reduced to 93, 89, 84 and 82 mmHg at the
end of 15 days, 1, 3 and 6 months respectively. The reduction in both systolic and diastolic
blood pressure from day 15 to month 6 was statistically significant (p < 0.0001) with
olmesartan treatment. The percentage of responders for both systolic and diastolic blood
pressure increased consistently from day 15 to month 6. Only 0.08% patients reported the
adverse events. No serious adverse event was reported in the study.
Conclusion: Olmesartan 20 mg/40 mg is effective and well tolerated without any serious
adverse events in patients with hypertension.
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High blood pressure is a major public health problem in many
countries including India.1 The prevalence of hypertension in
India among urban and rural populations is 25% and 10%
respectively and continues to increase rapidly.1 Changing so-
cioeconomic milieu with consequent changes in the lifestyles
of general public are believed to be the major determinants of
the rise in the prevalence of hypertension in India.2
Hypertension is one of the major contributors of cardio-
vascular morbidity and mortality worldwide. It is therefore
important to adequately control the blood pressure (BP) to
reduce the complications associated with hypertension. The
treatment of hypertension has been shown to significantly
reduce the incidence of stroke, myocardial infarction and
heart failure.3Various treatment modalities including non-
pharmacological and pharmacological are available for the
management of hypertension.1 Among the pharmacological
treatment options, multiple classes of drugs with different
mechanismof actionare availablewhich canbe selectedbased
on individual patient characteristics. Given the important role
of renineangiotensinealdosterone system in regulating blood
pressure, it becomes an important target of therapy aimed at
treating hypertension. Angiotensin receptor blockers (ARBs)
aremodulators of the renineangiotensinealdosterone system
and act by blocking the receptor responsible for the action of
angiotensin II. ARBs have been shown to be highly effective in
the management of hypertension as monotherapy or in com-
bination with other drugs.4 Olmesartan medoxomil is an ARB
with excellent efficacy and tolerability profile. It has long half-
life which ensures effective BP control over the 24 h dosing
interval. As a result, once daily dosing is required making the
dosing regimen simple and improving patient compliance.5
Other advantages of olmesartan include a lower incidence of
drug interactions and lack of the effect of age on its pharma-
cokinetic profile.2. Objective
The objective of this study was to evaluate the efficacy and
safety of WIN-BP (Olmesartan 20 mg/40 mg) tablet in Indian
patients with hypertension.3. Material and methods
An open label, non-comparative, multi-centric, real world
post marketing observational studywas conducted in existing
or newly diagnosed hypertensive Indian patients. Adults pa-
tients (>18 years) of either sex, with essential hypertension or
hypertension with co-morbidities such as angina, diabetes
mellitus, dyslipidemia or mild to moderate heart failure were
included in this study. The patients whose BP was not
controlled with single antihypertensive agent were also
included in this study. Pregnant and lactating women, pa-
tients with history of hypersensitivity to olmesartan, those
with severe cardiac failure, renal artery stenosis, chronic renal
failure, clinically significant hepatic or renal impairment,varicose veins, chronic venous insufficiency associated with
edema or any significant uncontrolled illness were not
included in the study. Patients who were on concomitant
medications like oral contraceptives, non-steroidal anti-in-
flammatory drugs, diuretics, vasodilators, digoxin, anticoag-
ulants were also excluded from the present study.
Patients satisfying the enrollment criteria were enrolled
after written informed consent and were started treatment
with olmesartan 20mg/40mg tablet once daily for sixmonths.
Dose titration was allowed as per the discretion of the treating
physician. The patients were followed for six months which
included a total of six visits (baseline, 15 days, 1 month, 2
month, 3 month, 6 month).
The primary outcome of the studywas reduction in systolic
BP (SBP) to 140mmHg and diastolic BP (DBP) to 90 mmHg at
3 and 6 months of treatment with olmesartan. Global
assessment for efficacy and tolerability was done by the
treating physician and the patient himself/herself at the end
of 6 months. All reported adverse events were recorded.
The study was conducted as per the applicable local and
national regulatory laws and guidelines and as per the GCP
guidelines of ICMR. The study protocol was approved by an
independent ethics committee.
3.1. Evaluation criteria
Percentage of patients who achieved SBP140mmHg andDBP
90 mmHg at 3 months and 6 months of treatment were
calculated. The absolute reduction in SBP andDBP at each visit
compared to baseline was also studied for the significance of
the difference. Global assessment of efficacywas done by both
the patient and the doctor on a four-point scale i.e.
4 ¼ excellent, 3 ¼ good, 2 ¼ moderate and 1 ¼ poor. The
tolerability was also assessed by both the patients and the
doctors and was graded as e “good: mild/no adverse effects”,
“moderate: adverse events of moderate intensity” and “poor:
adverse events-severe or discontinuation of therapy”.
3.2. Statistical analysis
The analysis was done on intention-to-treat basis and
included all patients who received at least one dose of study
medication. Paired t-test and repeat measures ANOVA were
used to assess the statistical significance of the differences in
SBP and DBP between the baseline and the follow up visits.
Chi-square test was used to compare the proportion of the
patients achieving adequate BP control (defined above). A p
value <0.05 was considered statistically significant.4. Results
4.1. Baseline characteristics
A total of 8940 patients were enrolled in this study. The mean
age, height and weight of the study patients are given in
Table 1. Most of the patients included in the study were be-
tween 18 and 65 years of age while 11.2% patients were above
65 years of age. Nearly two-thirds (65.2%) of all study patients
were males.
Table 1 e Baseline characteristics.
Parameter n Mean (SD)
Age (years) 8931 53.26 (10.34)
Height (cm) 4628 164.2 (9.74)
Weight (kg) 7196 69.98 (18.63)
Fig. 2 e Reduction in diastolic blood pressure.
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had ischemic heart disease. A substantial proportion of the
patients were previously on antihypertensive agents with
ARBs being the most common (87.2%) followed by beta
blockers (14.2%), calcium channel blockers (13.8%), diuretics
(9.7%), angiotensin converting enzyme (ACE) inhibitors (5.3%),
vasodilators (2.0%) and others (13.4%). Olmesartan was added
to existing antihypertensive treatment for controlling blood
pressure, if found suitable.Fig. 3 e Responders for systolic blood pressure
(£140 mmHg).4.2. Antihypertensive efficacy of olmesartan
Olmesartan was used in two strengths (20 mg/day and 40 mg/
day). Out of 8940 patients, 56.6% patients received olmesartan
20 mg/day while 40.9% patients received 40 mg/day. Concom-
itant medications received by more than 1% patients included
oral hypoglycemic agents (2.83%), statins (1.76%), angiotensin
receptor blockers (1.32%) and beta blockers (1.15%).
The baseline BP of the study patients was 164 mmHg sys-
tolic and 99.84 mm of Hg diastolic. Olmesartan significantly
reduced the BP throughout the study period. Statistically sig-
nificant reductions in both SBP andDBPwere seen from day 15
itself and the magnitude of reduction continued to increase
till the end of the study (i.e. 6 months’ follow-up) (Repeat
measures ANOVA p< 0.0001) (Figs. 1 and 2). At each of the visit
the difference i.e. reduction in blood pressure compared to
baseline was significant.
Mean change in the SBP from the baseline at the end of
first, third and six months were 19.08, 29.79 and 34.53 mm of
Hg respectively.
Mean change in DBP from baseline at the end of first, third
and six months were 11.07, 16.3 and 18.08 mm of Hg
respectively.
The percentage of responders for SBP defined as patients
with SBP 140 mmHg increased consistently from day 15 to
month 6 as shown in Fig. 3.
Similarly, there was a constant increase in the percentage
of DBP responders (patients with DBP 90 mmHg blood pres-
sure) also, from day 15 to month 6 (Fig. 4).Fig. 1 e Reduction in systolic blood pressure.When assessed by patients, the global assessment of
response to therapy was good to excellent in most of the pa-
tients at six months (Fig. 5). Three forth of the patients at the
end of six months rated the response as “excellent”.
Similarly, the global assessment of response to therapy
was rated as good by most (96.5%) of the treating physicians
also (Fig. 6).Fig. 4 e Responders for diastolic blood pressure
(£90 mmHg).
Fig. 5 e Global assessment of response to therapy by
patients at 6 months (n [ 8788).
Table 2 e Incidence of adverse events (n[ 8940).
Adverse event Percentage of patients
Edema 0.05%
Uncontrolled hypertension 0.03%
Dizziness 0.03%
Vertigo 0.03%
Fig. 7 e Global assessment of tolerability by patients at 6
months (n [ 8804).
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Olmesartan was extremely well tolerated in the study pa-
tients. Adverse events were reported by only 3 (0.08%) pa-
tients. The reported adverse events included edema,
dizziness, uncontrolled hypertension and vertigo (Table 2). No
serious adverse event was reported in this study.
As per the global assessment, the tolerability at 6 months
was rated as good by 96.49% and 96.48% patients when
assessed by the patients and the treating physicians respec-
tively (Figs. 7 and 8).5. Discussion
ARBs are very commonly used agents in the management of
hypertension. They are particularly preferred in numerous
clinical conditions such as left ventricular hypertrophy, renal
dysfunction, microalbuminuria, patients with previous
myocardial infarction, heart failure, metabolic syndrome as
well as diabetes mellitus.6 Among all the ARBs, olmesartan is
considered to be one of the most powerful antihypertensive
agents. In a previous multicenter, randomized, double-blind
clinical study, the antihypertensive efficacy of olmesartan
20 mg once daily was compared with recommended starting
doses of other ARBs i.e. losartan 50 mg, valsartan 80 mg, andFig. 6 e Global assessment of response to therapy by
doctors at 6 months (n [ 8804).irbesartan 150 mg. The results demonstrated that olmesartan
at its starting dose was more effective than the starting doses
of the other studied ARBs in reducing cuff DBP in essential
hypertension.7
Olmesartan has been available in India for several years
now for the treatment of hypertension. However, its safety
and efficacy has not been specifically assessed adequately in
Indian patients. Rana et al studied the efficacy and safety of
olmesartan 20 mg/d in an open label, multicentre, obser-
vational, post-marketing surveillance in adult Indian pa-
tients with stage 1 hypertension.8 Olmesartan 20 mg once
daily was found to be effective in BP reduction and also
showed an excellent tolerability profile. Our results from
this much larger study are in line with these previous ob-
servations. In addition, our study also evaluated the efficacyFig. 8 e Global assessment of tolerability by doctors at 6
months (n [ 8818).
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confirmed the efficacy and safety of olmesartan 40 mg/d in
hypertension management. The consistent improvement in
the efficacy of olmesartan was observed throughout the
study period. Almost 96% physicians rated the global effi-
cacy of olmesartan as “good”, demonstrating its effective-
ness in significantly reducing the BP. Furthermore, the
therapeutic benefit was observed with once daily dosing
which suggests that olmesartan is suitable for once daily
administration. These findings are in accordance with the
previous data showing sustained BP lowering during the
entire 24-h dosage interval with olmesartan administered
once daily.9,10
It has been reported that olmesartan has rapid onset of
action, with significant BP lowering effect seen from 2 weeks
onwards.8 In our study also, significant reductions in SBP and
DBP were seen from second visit (i.e. at 15 days) itself.
In terms of tolerability, the excellent safety profile of
olmesartanwas observedwith no patient showing any serious
adverse events and very low overall incidence of adverse
events.
Olmesartan 20 mg and 40 mg per day is an excellent
addition to the armamentarium of the antihypertensive drugs
for managing hypertension in Indian patients.6. Limitation
This study had some limitations that merit attention. The
most important limitation was its open label and non-
comparative study design. However, this is a recognized
well-accepted limitation of all post-marketing surveillance
studies. Though such study design introduces bias in the
assessment of therapeutic response and safety of the drug
being studied, post-marketing surveillances still provide
valuable insights in to the performance of the study drug in
real-life clinical setting. For this purpose, post-marketing
surveillances remain the only option as this kind of infor-
mation cannot be derived from any other form of study. Thus
our study too demonstrated excellent safety profile and
antihypertensive efficacy of olmesartan in regular clinical
practice However, in order to provide a counter-check
mechanism to mitigate, at least to some extent, the poten-
tial reporting bias, we also recorded the patients’ own
perception of the efficacy and tolerability of the drug. Con-
sistency of the patients’ assessment with that of the in-
vestigators provides further evidence of the accuracy and the
validity of the study findings.7. Conclusion
This post marketing, real world study demonstrates the effi-
cacy and safety of olmesartan 20 mg/40 mg in Indian adult
patients with hypertension, making olmesartan an effective
and well tolerated suitable treatment option for both newly
diagnosed patients as well as for patients whose BP is not
adequately controlled with other antihypertensive agents.
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